肝胆胰腺肿瘤综合治疗进展.pptxVIP

肝胆胰腺肿瘤综合治疗进展;2015-11-09;中国恶性肿瘤发病率;;2015-11-09;;早期肝癌放疗结果; 不能手术肝癌放疗结果;;肝癌伴门静脉/下腔静脉癌栓的放疗;肝癌腹腔淋巴结转移的放疗;;;;;;;;;;;;;;;;;;;;;;;肝癌放疗的价值;;intrahepatic CCA (iCCA),;Shahid A Khan,et al.Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update;Surgery;studies of surgery alone reporting data on survival;Prognosis;Patterns of Recurrence Resection of Biliary Tract Cancer;Pattern of recurrence according to primary tumor origin; patients (n) with recurrence;;unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection;Multidisciplinary Management;META-POSTOPERATION 35 TRAILS;survival of the selected studies of ART;;;;Twenty studies involving 6,712 patients were analyzed;Efficacy outcomes for overallpopulation;Efficacy outcomes for node positivedisease;Efficacy outcomes for marginpositive disease;Neo-adjuvant therapy ;Conclusions;The CORGI-U study;Conclusions ;Overall survival and Progression-free survival ;ABC-02 randomly phase 2 study ClinicalTrials.gov number, NCConclusion;;Targeted therapy;;Phase II and Phase III clinical trials investigating targeted agents in BTC;结 论;不能手术切除的局部晚期病变同步放化疗是标准治疗，50Gy/25-28f，每周同步XILOX或GP方案； 转移性胆管癌姑息化疗较BSC延长OS和PFS；GP较单药gemcitabine延长PFS3个月，是标准一线方案； 初步研究表明西妥昔单抗联合GP能获得较好的控制率，但需多中心，随机III期临床试验进一步证实。 ;;;;局限无远地转移可手术切除 5年生存率 15%-20% 中位生存期 12-20个月 局部进展无远地转移 中位生存期 6-10个月 已远地转移 中位生存期 3-6个月 ;中国2340例胰腺癌手术病例分析结果;;;;;;;;;可切除胰腺癌的辅助和新辅助治疗临床研究;;;;;;;;;;;;;;;;;;;;结果;;;;;提高剂量可提高疗效;不能手术切除的局部晚期胰腺癌，同步放化疗是标准治疗;; Before 1 month after;;;;;;总结